Holen Sie sich die Stockscreener-App
152.28
0.37%
0.91
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$151.37
Offen:
$151.1
24-Stunden-Volumen:
1.46M
Relative Volume:
0.23
Marktkapitalisierung:
$189.03B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
20.72
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+0.69%
1M Leistung:
+3.54%
6M Leistung:
+10.01%
1J Leistung:
+33.66%
1-Tages-Spanne:
$149.69
$152.97
1-Wochen-Bereich:
$148.22
$154.20
52-Wochen-Spanne:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
152.45 | 187.69B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,192.64 | 1.03T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.25 | 648.67B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.89 | 468.43B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.12 | 365.34B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.94 | 271.25B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences, Inc. (GILD) stock price, news, quote and history - Yahoo Finance Singapore
Gilead Sciences stock slips 0.85 percent ahead of the open - AD HOC NEWS
Gilead: HIV Growth Is Not Enough At The Current Price (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences stock slips 1.30 percent at the close - AD HOC NEWS
Gilead Sciences stock slips as earnings estimates shift - AD HOC NEWS
Can Gilead Sciences (NASDAQ:GILD) turn HIV leadership and oncology development into a stronger market story? - Kalkine Media
Gilead Sciences stock slips 0.7 percent ahead of the open - AD HOC NEWS
Gilead Sciences Research Scholars Program in Solid Tumors – US 2026 - oncodaily.com
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know - Yahoo Finance
Gilead Sciences stock slips 0.7 percent at the close - AD HOC NEWS
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Andra AP fonden Sells 11,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences FY2026 EPS Increased by Erste Group Bank - MarketBeat
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today - Benzinga
Gilead Sciences stock holds near 52-week high as HIV prevention deal and analyst optimism support va - AD HOC NEWS
Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring Revenue Growth and Strategic Collaborations - DirectorsTalk Interviews
Erste Group Bank Estimates Gilead Sciences FY2027 Earnings - MarketBeat
Gilead Sciences stock heads into the open after a 0.52% dip - AD HOC NEWS
Gilead Sciences stock gains as HIV drug access expands - AD HOC NEWS
Why Morgan Stanley likes Gilead’s HIV prevention play - thestreet.com
GILD: Gilead SciencesStock Price, Quote and News | NASDAQ - TechGraph
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries? - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Wall Street Zen - MarketBeat
Why Is Gilead Sciences (NASDAQ:GILD) in Focus Across S&P 500? - Kalkine Media
Nykredit A S Invests $140.59 Million in Gilead Sciences, Inc. $GILD - MarketBeat
[Press releases] Gilead Sciences provides updates on access to lenacapavir for HIV prevention - European AIDS Treatment Group
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance
Gilead Sciences (GILD) CFO Andrew Dickinson Sells 3,000 Shares a - GuruFocus
After $435,870 sale, Gilead (NASDAQ: GILD) CFO still holds 164K shares - Stock Titan
Gilead (NASDAQ: GILD) exec sells 3,000 shares in pre-arranged trades - Stock Titan
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention - Business Wire
Another 3,000-share sale planned by Gilead (NASDAQ: GILD) executive - Stock Titan
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances - Yahoo Finance
Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean - Reuters
Gilead Sciences Inc's Dividend Analysis - Yahoo Finance
California State Teachers Retirement System Sells 5,406 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences (GILD) Reasonable Given Its Sales Base? - Yahoo Finance
Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring a 10% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know - Yahoo Finance
Gilead Research Scholars Program in Solid Tumors 2026 - Oncodaily
Gilead Sciences, Inc. $GILD Stock Holdings Cut by Corient Private Wealth LP - MarketBeat
Sequoia Financial Advisors LLC Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
The Manufacturers Life Insurance Company Sells 148,344 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bullseye Investment Management LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
RSU vesting leaves Gilead (NASDAQ: GILD) CMO with 270 new shares after tax - Stock Titan
Gilead Sciences stock gains support as HSBC lifts price target to USD 175 - ad-hoc-news.de
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales - Yahoo Finance
Gilead Advances $32B U.S. Investment With New California Research Center - Business Facilities
Why is Gilead Sciences (NASDAQ:GILD) stock in focus today? - Kalkine Media
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):